5.90Open5.90Pre Close0 Volume49 Open Interest15.00Strike Price0.00Turnover1565.57%IV0.58%PremiumJul 19, 2024Expiry Date5.78Intrinsic Value100Multiplier0DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type0.8999Delta0.0295Gamma3.41Leverage Ratio-4.2434Theta0.0000Rho3.07Eff Leverage0.0007Vega
Nurix Therapeutics Stock Discussion
as this guy 👇
$Taysha Gene Therapies(TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US)$ 14% Clinical programs update
$Jaguar Health(JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US)$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US)$ 0...
Nurix said patients currently enrolled in the trial who are deriving clinical benefit are allowed to continue receiving the current drug product. The screening and enrollment of new patients has been paused.
The company sai...
No comment yet